文献速递生殖医学

新鲜体外受精周期中孕激素黄体期支持的评估

Evaluation of progestogen supplementation for luteal phase support in fresh in vitro fertilization cycles.
PubMed 文献 · Fertil Steril · 2019-06-11

该系统综述与荟萃分析纳入82篇文章(26,726名女性),评估新鲜IVF周期中孕激素补充对临床妊娠率的影响。与未治疗相比,肌注、阴道、皮下或口服孕激素均提高临床妊娠率;肌注获益最大,取卵后1天开始最佳,雌激素联合给药无获益,孕激素使用超过3周无额外获益。

要点

  • 与未治疗相比,肌注(OR=4.57)、阴道(OR=3.34)、皮下(OR=3.36)或口服(OR=2.57)孕激素补充均提高临床妊娠率。
  • 肌注孕激素较阴道给药临床妊娠率更高(OR=1.37),取卵后1天开始给药获益最大。
  • 雌激素联合给药无获益(OR=1.33),孕激素使用≤3周与延长至12周的临床妊娠率相当(OR=1.06)。

核心结论

  • 该广泛荟萃分析提示需重新评估当前临床实践,新鲜IVF周期中使用孕激素对临床妊娠有实质性获益。
  • 肌注孕激素不应被摒弃,其临床妊娠率最高。
  • 治疗启动时间影响妊娠成功,取卵后1天为最佳。
  • 几乎没有证据支持雌激素联合给药或将孕激素治疗延长至3周以上。

研究设计与样本

  • 综合系统综述与荟萃分析,纳入82篇文章(26,726名女性),对象为接受新鲜IVF周期且接受或不接受孕激素补充的女性。
  • 通过二项逻辑回归计算汇总比值比(OR),主要结局为临床妊娠率。

主要发现

  • 与未治疗相比,肌注孕激素补充提高临床妊娠率(OR=4.57)。
  • 与未治疗相比,阴道孕激素补充提高临床妊娠率(OR=3.34)。
  • 与未治疗相比,皮下孕激素补充提高临床妊娠率(OR=3.36)。
  • 与未治疗相比,口服孕激素补充提高临床妊娠率(OR=2.57)。
  • 肌注较阴道给药临床妊娠率更高(OR=1.37),取卵与胚胎移植之间开始给药最佳(OR=1.31),取卵后1天开始获益最大。

关键数值与推荐

  • 雌激素联合给药无获益(OR=1.33),无论孕激素经阴道或肌注联合给药。
  • 孕激素补充≤3周后停药与持续至12周的临床妊娠率相当(OR=1.06)。

临床怎么用

  • 原文结论认为新鲜IVF周期中使用孕激素对临床妊娠有实质性获益,肌注孕激素不应被摒弃。
  • 原文结论认为取卵后1天开始孕激素治疗为最佳。
  • 原文结论认为几乎没有证据支持雌激素联合给药或将孕激素治疗延长至3周以上。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of progestogen supplementation in improving clinical pregnancy rates in women undergoing fresh IVF cycles and to compare different routes, start times, durations, and estrogen coadministration regimen. DESIGN: Comprehensive systematic review and meta-analysis. SETTING: University. PATIENT(S): Women undergoing fresh IVF cycles who did and did not receive progestogen supplementation. INTERVENTION(S): Summary odds ratios (ORs) were calculated by binomial logistic regression. MAIN OUTCOME MEASURE(S): Clinical pregnancy rates. RESULT(S): Eighty-two articles (26,726 women) were included. Clinical pregnancy rates were increased by IM (OR = 4.57), vaginal (OR = 3.34), SC (OR = 3.36), or oral (OR = 2.57) progestogen supplementation versus no treatment. The greatest benefit was observed when progestogens were supplemented IM versus vaginally (OR = 1.37). The optimal time to commence administration was between oocyte retrieval and ET (OR = 1.31), with oocyte retrieval +1 day being most beneficial. Coadministration of estrogen had no benefit (OR = 1.33), whether progestogens were coadministered vaginally or IM. Clinical pregnancy rates were equivalent when progestogen supplementation was ceased after ≤3 weeks or continued for up to 12 weeks (OR = 1.06). CONCLUSION(S): This broad-ranging meta-analysis highlights the need to reevaluate current clinical practice. The use of progestogens in fresh IVF cycles is substantially beneficial to clinical pregnancy. Critically, the use of IM progestogens should not be dismissed, as it yielded the greatest clinical pregnancy rates. Pregnancy success was impacted by initiation of therapy, with 1 day after oocyte retrieval being optimal. There is little evidence to support coadministration of estrogen or prolonging progestogen treatment beyond 3 weeks.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Mohammed A, Woad KJ, Mann GE, et al. Evaluation of progestogen supplementation for luteal phase support in fresh in vitro fertilization cycles. Fertil Steril. 2019. PMID: 31200970. doi:10.1016/j.fertnstert.2019.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。